Tirzepatide Drug Interactions
Also known as: Mounjaro, Mounjaro KwikPen, Zepbound
Tirzepatide is a once-weekly injectable prescription medication that activates both the GIP and GLP-1 hormone receptors — making it the first dual GIP/GLP-1 receptor agonist approved by the FDA. It is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea. Clinical trials show it reduces HbA1c by up to 2.58 percentage points and body weight by up to 20.9% at the highest dose.Tirzepatide has 2 documented drug interactions in our database, including 0 contraindicated, 0 major, 2 moderate, and 0 minor interactions.
0
Contraindicated
0
Major
2
Moderate
0
Minor
Combining metformin and tirzepatide can increase the risk of hypoglycemia (low blood sugar) because both medications work to lower blood glucose levels. Patients may experience symptoms such as dizziness, sweating, confusion, or shakiness.
Mechanism
Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, while tirzepatide (a GIP and GLP-1 receptor agonist) enhances insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. The additive glucose-lowering effects of these two agents can lead to an increased risk of hypoglycemia.
Clinical Management
Patients should be educated on the signs and symptoms of hypoglycemia and how to manage it. Blood glucose levels should be monitored regularly, especially when starting tirzepatide or increasing its dose. Dose adjustments of metformin or other concomitant diabetes medications may be necessary to minimize hypoglycemia risk.
Tirzepatide can delay gastric emptying, which may affect the absorption rate and extent of orally administered medications like warfarin. While no specific interaction study with warfarin has been conducted, this potential change in absorption could theoretically alter warfarin's anticoagulant effect, increasing the risk of bleeding or thrombosis.
Mechanism
Tirzepatide, as a GLP-1/GIP receptor agonist, slows gastric emptying. This delayed transit through the gastrointestinal tract could lead to altered absorption kinetics of concurrently administered oral medications, potentially affecting the time to peak concentration (Tmax) and overall exposure (AUC) of warfarin.
Clinical Management
Patients receiving warfarin should be closely monitored for changes in their INR, especially when initiating or discontinuing tirzepatide, or during dose escalation. Adjustments to the warfarin dose may be necessary based on INR monitoring to maintain the therapeutic range and prevent adverse events.
For complete prescribing information:
View full Tirzepatide monograph →Already managing multiple medications?
Compare prices for all your prescriptions at 67,000+ pharmacies with one free RxGo search.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.